Cigna · Anifrolumab · US health-plan appeal rights

Anifrolumab denied as duplicate or overlapping therapy by Cigna?

Q: How long do I have to appeal a Cigna Anifrolumab denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-09

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Cigna typically requires

Adult ≥18 yr with moderate-to-severe SLE meeting EULAR/ACR 2019 criteria, on standard therapy (HCQ + GC ± MMF/AZA/MTX) with active disease (SLEDAI-2K ≥6 or BILAG A in any organ). 300 mg IV q4wk. Type-I IFN gene signature testing not required. Reauth 6 mo with BICLA response or SLEDAI-2K reduction ≥4 with GC taper.

Source policy: Cigna Pharmacy Coverage Policy 2073: Saphnelo (Anifrolumab-fnia) for Moderate-to-Severe SLE

What works in the appeal

TULIP-2 NEJM 2020 met BICLA primary endpoint 47.8% vs 31.5% placebo (p=0.001); pooled TULIP-1+TULIP-2 reanalysis using BICLA showed consistent benefit. FDA approved Aug 2021 based on totality of evidence including MUSE Phase 2. EULAR 2023 places anifrolumab equal-weight with belimumab for non-renal SLE refractory to standard ISD — NO mandated sequence. Saphnelo blocks type-I-IFN receptor (IFNAR1) — distinct mechanism from BLyS-targeting belimumab; failure of one does not predict the other. LN exclusion is appropriate; this request is for non-renal moderate-to-severe SLE with active cutaneous + musculoskeletal + serologic disease.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Cigna appeals

Other denial reasons for Cigna Anifrolumab

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-09. Editorial standards: denialhelp.com/authors.